Identification of Tumor Microenvironment-Related Alternative Splicing Events to Predict the Prognosis of Endometrial Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 May 17

PMID 33996564

Citations 4

Authors

Xuan Liu

Chuan Liu

Jie Liu

Ying Song

Shanshan Wang

Miaoqing Wu

Shanshan Yu

Luya Cai

Affiliations

Soon will be listed here.

Abstract

Background: Endometrial cancer (EC) is one of the most common female malignant tumors. The immunity is believed to be associated with EC patients' survival, and growing studies have shown that aberrant alternative splicing (AS) might contribute to the progression of cancers.

Methods: We downloaded the clinical information and mRNA expression profiles of 542 tumor tissues and 23 normal tissues from The Cancer Genome Atlas (TCGA) database. ESTIMATE algorithm was carried out on each EC sample, and the OS-related different expressed AS (DEAS) events were identified by comparing the high and low stromal/immune scores groups. Next, we constructed a risk score model to predict the prognosis of EC patients. Finally, we used unsupervised cluster analysis to compare the relationship between prognosis and tumor immune microenvironment.

Results: The prognostic risk score model was constructed based on 16 OS-related DEAS events finally identified, and then we found that compared with high-risk group the OS in the low-risk group was notably better. Furthermore, according to the results of unsupervised cluster analysis, we found that the better the prognosis, the higher the patient's ESTIMATE score and the higher the infiltration of immune cells.

Conclusions: We used bioinformatics to construct a gene signature to predict the prognosis of patients with EC. The gene signature was combined with tumor microenvironment (TME) and AS events, which allowed a deeper understanding of the immune status of EC patients, and also provided new insights for clinical patients with EC.

Citing Articles

The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer.

Cao M, Yan J, Ding Y, Zhang Y, Sun Y, Jiang G Cell Death Dis. 2025; 16(1):148.

PMID: 40032844 PMC: 11876696. DOI: 10.1038/s41419-025-07458-7.

Prognostic importance of splicing-triggered aberrations of protein complex interfaces in cancer.

Newaz K, Schaefers C, Weisel K, Baumbach J, Frishman D NAR Genom Bioinform. 2024; 6(3):lqae133.

PMID: 39328266 PMC: 11426328. DOI: 10.1093/nargab/lqae133.

Alternative splicing of mediated by genetic variants is significantly associated with endometrial cancer risk.

He S, Cao R, Mao Y, Li N, Wang Y, Ma H J Gynecol Oncol. 2023; 34(3):e40.

PMID: 36731897 PMC: 10157344. DOI: 10.3802/jgo.2023.34.e40.

Identification of Alternative Splicing-Related Genes CYB561 and FOLH1 in the Tumor-Immune Microenvironment for Endometrial Cancer Based on TCGA Data Analysis.

Sun D, Zhang A, Gao B, Zou L, Huang H, Zhao X Front Genet. 2022; 13:770569.

PMID: 35836577 PMC: 9274141. DOI: 10.3389/fgene.2022.770569.

Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment.

Yue C, Zhao T, Zhang S, Liu Y, Zheng G, Zhang Y Sci Rep. 2022; 12(1):980.

PMID: 35046435 PMC: 8770494. DOI: 10.1038/s41598-021-03836-1.

References

De Nola R, Menga A, Castegna A, Loizzi V, Ranieri G, Cicinelli E . The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication. Int J Mol Sci. 2019; 20(10). PMC: 6567055. DOI: 10.3390/ijms20102401. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E . Endometrial cancer. Lancet. 2015; 387(10023):1094-1108. DOI: 10.1016/S0140-6736(15)00130-0. View

Vanderstraeten A, Tuyaerts S, Amant F . The immune system in the normal endometrium and implications for endometrial cancer development. J Reprod Immunol. 2015; 109:7-16. DOI: 10.1016/j.jri.2014.12.006. View

Chen P, Yang Y, Zhang Y, Jiang S, Li X, Wan J . Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer. Aging (Albany NY). 2020; 12(4):3371-3387. PMC: 7066904. DOI: 10.18632/aging.102817. View

Blasco M, Navas C, Martin-Serrano G, Grana-Castro O, Lechuga C, Martin-Diaz L . Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell. 2019; 35(4):573-587.e6. PMC: 10132447. DOI: 10.1016/j.ccell.2019.03.002. View

Drouet Y, Treilleux I, Viari A, Leon S, Devouassoux-Shisheboran M, Voirin N . Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. Sci Rep. 2018; 8(1):7386. PMC: 5943309. DOI: 10.1038/s41598-018-25631-1. View

Frankiw L, Baltimore D, Li G . Alternative mRNA splicing in cancer immunotherapy. Nat Rev Immunol. 2019; 19(11):675-687. DOI: 10.1038/s41577-019-0195-7. View

Ge Y, Porse B . The functional consequences of intron retention: alternative splicing coupled to NMD as a regulator of gene expression. Bioessays. 2013; 36(3):236-43. DOI: 10.1002/bies.201300156. View

10.

McEvoy C, Xu H, Smith K, Etemadmoghadam D, Leong H, Choong D . Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. J Clin Invest. 2019; 129(5):1940-1945. PMC: 6486352. DOI: 10.1172/JCI123089. View

11.

Frenel J, Le Tourneau C, ONeil B, Ott P, Piha-Paul S, Gomez-Roca C . Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36):4035-4041. DOI: 10.1200/JCO.2017.74.5471. View

12.

Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F . The clinical role of the TME in solid cancer. Br J Cancer. 2018; 120(1):45-53. PMC: 6325164. DOI: 10.1038/s41416-018-0327-z. View

13.

Digomann D, Linge A, Dubrovska A . SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed. Autophagy. 2019; 15(10):1850-1851. PMC: 6735542. DOI: 10.1080/15548627.2019.1639302. View

14.

Konstantinopoulos P, Luo W, Liu J, Gulhan D, Krasner C, Ishizuka J . Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019; 37(30):2786-2794. PMC: 9798913. DOI: 10.1200/JCO.19.01021. View

15.

Tlsty T . Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol. 1998; 10(5):647-53. DOI: 10.1016/s0955-0674(98)80041-0. View

16.

Brooks R, Fleming G, Lastra R, Lee N, Moroney J, Son C . Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019; 69(4):258-279. DOI: 10.3322/caac.21561. View

17.

Clarke M, Devesa S, Harvey S, Wentzensen N . Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. J Clin Oncol. 2019; 37(22):1895-1908. PMC: 6675596. DOI: 10.1200/JCO.19.00151. View

18.

Baralle F, Giudice J . Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017; 18(7):437-451. PMC: 6839889. DOI: 10.1038/nrm.2017.27. View

19.

He X, Ng D, Van Aelst L, Egeblad M . Stressing Out about Cancer Immunotherapy. Cancer Cell. 2019; 36(5):468-470. DOI: 10.1016/j.ccell.2019.10.013. View

20.

Zhan L, Rosenberg A, Bergami K, Yu M, Xuan Z, Jaffe A . Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell. 2008; 135(5):865-78. PMC: 3015046. DOI: 10.1016/j.cell.2008.09.045. View